Overview Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH Status: Recruiting Trial end date: 2024-02-01 Target enrollment: Participant gender: Summary The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in pediatric Chinese patients with XLH Phase: Phase 4 Details Lead Sponsor: Kyowa Kirin Co., Ltd.